Objectives and Expected Results >
View Program at a glance (pdf)
Wednesday, May 9, 2012
14:00 – 18:00 Registration
16:45 – 17:15 Welcome address
Ezio Giacobini, Gabriel Gold and Agneta Nordberg, Organizers
Arnaud Perrier, Head of the Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals (Geneva, Switzerland)
J. Kevin Dorsey, Dean, Southern Illinois University School of Medicine (Springfield, USA)
Harriet Wallberg Henriksson, Dean, Karolinska Institutet, (Stockholm, Sweden)
17:15 – 18:00 Opening Lecture:
Bengt Winblad (Stockholm, Sweden)
Alzheimer Therapy: Present and Future
Thursday, May 10, 2012
Room A
08:15 – 08:35 State of the art lecture
Bruno Dubois (Paris, France)
Validation and implementation of new diagnostic criteria for Alzheimer's disease
Are we Ready to Perform Clinical Trials in Early Alzheimer's Disease Patients?
Chairs: Serge Gauthier and Lon Schneider
09:35 – 09:55
Robert Becker (South Freeport, USA)
Are we ready with a new trial design?
09:55 – 10:45 Break
Special plenary session in rooms A and B:
Alzheimer’s Disease: The Health Challenge of the 21st Century
Chairs: Agneta Nordberg and Ezio Giacobini
10:45 – 11:00
Agneta Nordberg (Stockholm, Sweden)
Introduction
11:00 – 11:20
John Morris (St. Louis, USA)
Alzheimers’ disease: What have we learned and where must we go?
11:20 – 11:40
Rudolph Tanzi (Charlestown, USA)
What are genetic studies teaching us about how to treat Alzheimer’s disease?
11:40 – 12:00
Miia Kivipelto (Stockholm, Sweden)
Prevention of Alzheimer’s disease, is it possible?
12:00 – 12:20
Marco Trabucchi (Brescia, Italy)
Caring for patients with dementia
12:20 – 13:45 Lunch
Combination Treatment in Alzheimer’s Disease
13:45 – 15:25
(mini-symposium supported by H. Lundbeck, A/S)
15:25 – 15:55 Break
TBA
15:55 – 17:35
(mini-symposium supported by Pfizer, Janssen AI and the Alzheimer’s Immunotherapy Program)
Thursday, May 10, 2012
Room B
08:15 – 08:35 State of the art lecture: TBA
Concomitant activation of G-protein coupled receptors (GPCR) and sigmal receptor (Sig1R):
A novel pharmacological concept in treatment of Alzheimer’s disease (AD)
The Cholinergic System and Alzheimer's Disease - Year 2012
Chairs: Giancarlo Pepeu and Israel Hanin
08:35 – 08.55
Elliott Mufson (Chicago, USA)
Cholinergic and amyloid activity in prodromal Alzheimer's disease: Implications for disease treatment
08:55 – 09:15
Claudio Cuello (Montreal, Canada)
NGF and Alzheimer’s disease
09:15 – 09:35
Taher Darreh-Shori (Stockholm, Sweden)
The relationship between cholinesterases and Alzheimer's disease pathology
09:35 – 09:55
Amelia Marutle (Stockholm, Sweden)
Revamping the cholinergic system in Alzheimer’s disease: Experience from stem cell studies
(Session dedicated to David Bowen)
09:55 – 10:45 Break
10:45 – 12:20 Special plenary session in rooms A and B
Alzheimer’s Disease: The Health Challenge of the 21st Century (see room A)
12:20 – 13:45 Lunch
13:45 – 14:05 State of the art lecture:
Kaj Blennow (Mölndal, Sweden)
Testing new treatments with CSF biomarkers in early Alzheimer's disease patients
A-Beta Oligomers and Tau: Partners in Crime?
Chairs: Colin Masters and Lennart Mucke
14:05 – 14:25
Lennart Mucke (San Francisco, USA)
Mechanisms and treatment of A-beta-induced neuronal dysfunction
14:25 – 14:45
Dominic Walsh (Dublin, Ireland)
Getting to grips with water-soluble brain-derived A-beta dimers
William Klein (Evanston, USA)
Is tau phosphorylation the fuse and toxic A-beta the match?
15:05 – 15:25
Colin Masters (Parkville, Australia)
A-beta oligomers as diagnostic and therapeutic targets for Alzheimer’s disease
15:25 – 15:55 Break
15:55 – 16:15 State of the art lecture:
Luc Buée (Lille, France)
Innovative therapeutic strategies for TAU pathology: From cholesterol metabolism to immunotherapy
Phosphorylated-Tau: The Hottest Target in Town?
Chairs: Eva Mandelkow and Karen Ashe
16:15 – 16:35
Eva Mandelkow (Hamburg, Germany)
Reversibility of cognitive decline and synapse loss in regulatable mice with tau pathology
16:35 – 16:55
Karen Ashe (Minneapolis, USA)
Evidence in humans linking a specific amyloid-beta oligomer to tau pathobiology
16:55 –17:15
Khalid Iqbal (Staten Island, USA)
Promise and feasibility of inhibition of tau’s abnormal hyperphosphorylation
17:15 – 17:35
Maria Grazia Spillantini (Cambridge, UK)
Tauopathies: a single therapy for all?
Friday, May 11, 2012
Room A
08:30 – 08:50 State of the art lecture:
Laura Fratiglioni (Stockholm, Sweden)
Life course epidemiology in dementia – state of the art
Immunization: Is it the Right Solution?
Chairs: Roger Nitsch and Dale Schenk
08:50 – 09:10
Roger Nitsch (Zurich, Switzerland)
Immunotherapy of protein aggregation diseases
09:10 – 09:30
Dale Schenk (South San Francisco, USA)
Preclinical and clinical considerations for A-beta immunotherpay
09:30 – 09:50
Christoph Hock (Zurich, Switzerland)
Antibody therapy of Alzheimer’s disease
09:50 – 10:10
Ezio Giacobini (Geneva, Switzerland)
Taming beta-amyloid: Is that the solution?
10:10 – 10:40 Break
Advances in Molecular Imaging in Alzheimer’s Disease
Chairs: Agneta Nordberg and Lars Farde
10:40 – 11:00
Agneta Nordberg (Stockholm, Sweden)
A decade of amyloid PET imaging: Advances in neuroinflammation
11:00 – 11:20
TBA
11:20 – 11:40
Zsolt Cselényi (Södertälje, Sweden)
Early clinical development of amyloid-beta specific PET radioligand (18F) AZD4694
11:40 – 12:00
Victor Villemagne (Heidelberg, Australia)
In vivo tau imaging with PET
12:00 – 12:20
Round table discussion
(mini-symposium supported by AstraZeneca)
12:20 – 13:45 Lunch
13:45 – 14:05 State of the art lecture:
Pierre Magistretti (Lausanne, Switzerland)
Astrocyte-neuron metabolic coupling in Alzheimer’s disease
Using Imaging Markers to Study Drug Effects in Alzheimer’s Disease
Chairs: Bill Klunk and Nick Fox
14:05 - 14:25
Bill Klunk (Pittsburgh, USA)
The contribution of PET amyloid imaging to the study of drug effects
14:25 - 14:45
Nick Fox (London, UK)
MRI in the evaluation of therapeutic effects in clinical trials in early and presymptomatic Alzheimer's disease
14:45 - 15:05
Giovanni Frisoni (Brescia, Italy)
MRI, hypocampal atrophy and cognition
15:05 - 15:25
Juha Rinne (Turku, Finland)
Following drug effects with PET imaging markers
(Session partially supported by GE Healthcare)
15:25 – 15:55 Break
High-dose Cholinesterase Inhibition: A New Approach to AlzheimerTherapy?
Chairs: Gary Small and Ezio Giacobini
15:55 – 16:00
Chairmen’s introduction: Ezio Giacobini (Switzerland) and Gary Small, USA
16:00 – 16:20
Gary Small (Los Angeles, USA)
Pharmacological rationale for cholinesterase inhibition in Alzheimer’s disease
16:20 – 16:40
Martin Farlow (Indianapolis, USA)
Importance of achieving optimal cholinesterase inhibitor dose
16:40 – 17:00
Niels Andreasen (Stockholm, Sweden)
The underlying mechanism of action of cholinesterase inhibitors and its implications for long term Alzheimer’s disease management
17:00 – 17:20
Lutz Frölich (Mannheim, Germany)
High-dose rivastigmine patch: results from the OPTIMA study
17:20 – 17:35
Round table discussion / Q&A session
(mini-symposium supported by Novartis)
Friday, May 11, 2012
Room B
08:30 – 08:50 State of the art lecture:
Constantin Bouras (Geneva, Switzerland)
The brain of very old people: How does it work?
New Diagnostic Tools
Chairs: Hilkka Soininen and Panteleimon Giannakopoulos
08:50 – 09:10
Hilkka Soininen (Kuopio, Finland)
Predict Alzheimer's disease tools for early diagnosis
09:10 – 09:30
Harald Hampel (Frankfurt, Germany)
Novel hypothesis-based Alzheimer’s disease prediction biomarkers in blood and CSF
09:30 – 09:50
Jean-Marc Orgogozo (Bordeaux, France)
Prediction of dementia with simple clinical criteria in elderly subjects
09:50 – 10:10
Panteleimon Giannakopoulos (Geneva, Switzerland)
EEG-based prediction of rapid cognitive decline in MCI
10:10 – 10:40 Break
10:40 – 11:00 State of the art lecture:
Amos Korczyn (Ramat Aviv, Israel)
Why have we failed to cure Alzheimer’s disease?
Emerging Novel Therapeutic Targets I
Chairs: Marta Weinstock and Andreas Muhs
11:00 – 11:20
Marta Weinstock (Jerusalem, Israel)
Ladostigil, a novel multifunctional drug for the prevention and treatment of Alzheimer’s disease
11:20 – 11:40
Andreas Muhs (Lausanne, Switzerland)
Novel phospho-Tau specific liposome-based vaccines to treat Tau pathology
11:40 – 12:00
Moussa Youdim (Haifa, Israel)
Novel new multi target anti Alzheimer drugs with neuroprotective and neurorestorative activities
12:00 – 12:20
A. David Smith (Oxford, UK)
Disease-modification in mild cognitive impairment by lowering homocysteine
(Session partially supported by AC Immune, Switzerland)
12:20 – 13:45 Lunch
13:45 – 14:05 State of the art lecture:
Christopher Rowe (Melbourne, Australia)
Brain imaging in early detection of Alzheimer’s disease and other dementias
Vascular Dementia
Chairs: Gabriel Gold and Timo Erkinjuntti
14:05 – 14:25
Gabriel Gold (Geneva, Switzerland)
Cerebral microinfarcts: a key target in vascular cognitive impairment?
14:25 – 14:45
Philip Scheltens (Amsterdam, The Netherlands)
Cerebral microbleeds: identification, prevalence and clinical relevance
14:45 – 15:05
Timo Erkinjuntti (Helsinki, Finland)
Small vessel disease
15:05 – 15:25
Ingmar Skoog (Göteborg, Sweden)
Influence of mid-life risk factors on late life cognitive and white matter changes: how should we time preventive interventions?
15:25 – 15:55 Break
15:55 – 16:15 State of the art lecture:
Dina Zekry (Geneva, Switzerland)
Anti-oxidants in Alzheimer’s disease and MCI
Caring for Patients with Dementia
Chairs: Arnaud Perrier and Howard Bergman
16:15 – 16:35
Orazio Zanetti (Brescia, Italy)
Non-pharmacological intervention and caregiver support
16:35 – 16:55
Philippe Robert (Nice, France)
Management of neuropsychiatric symptoms in dementia
16:55 – 17:15
Howard Bergman (Montreal, Canada)
How should we structure care for Alzheimer patients?
17:15 – 17:35
Anders Wimo (Stockholm, Sweden)
Global pharmacoeconomics of Alzheimer’s disease in light of potential cost effectiveness of disease modifying treatment
Saturday, May 12, 2012
Room A
The Emerging Clinical Profile of Oral Scyllo-inositol (ELND005) in Alzheimer’s Disease: A Dual Mechanism of Action?
Chairs: Agneta Nordberg and Dale Schenk
08:30 – 08:50
Gene Kinney (San Francisco, USA)
Overview of amyloid and non-amyloid targets in AD drug development: Where does ELND005 fit in?
08:50 – 09:10
Constantine Lyketsos (Baltimore, USA)
Who are the responders to amyloid-based drugs? What we learned from ELND005 data
09:10 – 09:30
Susan Abushakra (San Francisco, USA)
What constitutes evidence of target engagement in AD trials? ELND005 CNS Pharmaco-kinetics, biomarker, and safety profile
09:30 – 09:50
Pierre Tariot (Phoenix, USA)
Neuropsychiatric symptoms in AD: Novel analytical approaches for disease modification trials
09:50 – 10:10
Roy Jones (Bath, UK)
Optimizing treatment success with early intervention: Is mild AD dementia early enough?
(mini-symposium supported by Elan)
10:10 – 10:40 Break
10:40 – 11:00 State of the art lecture:
Henry Riordan (King of Prussia, USA)
CSF sample acquisition and analyses for translational research purposes
(supported by Worldwide Clinical Trials, USA)
Non-Alzheimer's Disease Dementia: Diagnosis and Treatment
Chairs: Rodger Elble and Ian McKeith
11:00 – 11:20
Rodger Elble (Springfield, USA)
How similar and disimilar are Alzheimer's disease, PD, DLB and FTD?
11:20 – 11:40
Clive Ballard (London, UK)
Optimal treatment for Parkinson patients with cognitive disorders
11:40 – 12:00
Ian McKeith (New Castle, UK)
Early diagnosis for Lewy body disease and treatment
12:00 – 12:20
Andrew Kertesz (London, Canada)
Fronto-temporal degeneration, an update
13:45 – 14:05 State of the art lecture:
François Herrmann (Geneva, Switzerland)
Cognitive reserve and survival
Round Table: Let’s Treat Familial Alzheimer’s Disease (EOFAD)
Chairs: Serge Gauthier and Jianping Jia
14:05 – 14:15
Serge Gauthier (Montreal, Canada)
EOFAD: Opportunities for proof-of-concept studies to modify disease progression
14:15 – 14:25
Amalia Bruni (Lamezia Terme, Italy)
Let’s treat Alzheimer’s disease - Genetic aspects
14:25 – 14:35
Agneta Nordberg (Stockholm, Sweden)
EOFAD: Imaging and genetics
14:35 – 14:45
Jianping Jia (Beijing, China)
Chinese early-onset familial Alheimer’s disease
14:45 – 14:55
John Morris (St. Louis, USA)
EOFAD: Update on dominantly inherited Alzheimer network (DIAN)
14:55 – 15:30
General discussion
15:30 – 16:00
Closing Remarks
18:00 – 22:00 Speakers dinner (by invitation)
Saturday, May 12, 2012
Room B
08:30 – 08:50 State of the art lecture:
Hermona Soreq (Jerusalem, Israel)
Micro RNAs: a new therapeutic target in Alzheimer’s disease
Emerging Novel Therapeutic Targets II
Chairs: Howard Fillit and Beka Solomon
08:50 – 09:10
Hans-Ulrich Demuth (Halle, Germany)
Inhibition of Glutaminyl cyclase targeting neurodegeneration and neuroinflammation in
Alzheimer’s disease
09:10 – 09:30
Howard Fillit (New York, USA)
Novel programs in drug discovery for Alzheimer’s disease
09:30 – 09:50
Beka Solomon (Tel Aviv, Israel)
Beneficial effect of anti APP antibodies on Alzheimer’s pathology
09:50 – 10:10
Maria Eriksdotter Jönhagen (Stockholm, Sweden)
Cell therapy with nerve growth factor (NGF) in Alzheimer’s disease
(session partially supported by Probiodrug AG, Germany)
10:10 – 10:40 Break
Emerging Novel Therapeutic Targets III
Chairs: Bengt Winblad and Achim Schneeberger
10:40 – 11:00
Markus Mandler (Vienna, Austria)
Affitope® – Based vaccines: A novel and safe immunotherapeutic strategy for neurodegenerative diseases
11:00 – 11:20
Achim Schneeberger (Vienna, Austria)
Affitope® Alzheimer vaccines – Results from phase I support the further clinical development of Affitope AD02
11:20 – 11:40
Giulio Pasinetti (New York, USA)
Repurposing anti-hypertensive drugs for Alzheimer’s disease
11:40 – 12:00
Richard Fisher (Cambridge, USA)
NPT002: A novel approach for targeting A-beta amyloid and tau aggregates in Alzheimer’s disease
12:00 – 12:20
David Gelmont (Westlake Village, USA)
The safety and effectiveness of immune globulin intravenous (human), for the treatment of mild to moderate Alzheimer’s disease
(session partially supported by Affiris GmbH, Austria; NeuroPhage Pharmaceuticals. USA and Baxter Bioscience, Baxter Healthcare Corp. USA)
12:20 – 13:45 Lunch
13:45 – 14:05 State of the art lecture:
Manfred Windisch (Graz, Austria)
Animal models for preclinical testing of early Alzheimer’s disease?
Is ApoE a Valid Target for Treatment of Alzheimer’s Disease?
Chairs: Daniel Michaelson and David Holtzman
14:05 – 14:25
Daniel Michaelson (Tel Aviv, Israel)
ApoE4 potentiates the amyloid cascase and inhibits neuroprotective mechanisms: prevention of these effects by DHA diet
14:25 – 14:45
Michela Pievani (Brescia, Italy)
Relation of ApoE to brain structure and function in Alzheimer’s disease and aging
14:45 – 15:05
David Holtzman (St. Louis, USA)
Effect of anti-apoE antibodies on A-beta pathology and accumulation
15:05 – 15:25
Gary Landreth (Cleveland, USA)
ApoE-directed therapeutics for the treatment of Alzheimer’s disease
15:30 – 16:00 Closing remarks in room A
18:00 – 22:00 Speakers dinner (by invitation)